


Abstract

The present invention relates to cyclic amine derivatives of formula(I)



wherein

R represents halogen, C₁₋₄ alkyl, cyano, C₁₋₄ alkoxy, trifluoromethyl or trifluoromethoxy;

R₁ represents hydrogen, halogen, C₃₋₇cycloalkyl, hydroxy, nitro, cyano or C₁₋₄ alkyl optionally substituted by halogen, cyano or C₁₋₄ alkoxy;

R₂ represents hydrogen or C₁₋₄ alkyl;

R₃ and R₄ independently represent hydrogen, cyano, C₁₋₄ alkyl or R₃ together with R₄ represents C₃₋₇ cycloalkyl;

R₅ represents trifluoromethyl, S(O)_t C₁₋₄ alkyl, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethoxy, halogen or cyano;

R₆ represents hydrogen or (CH₂)_rR₇;

R₇ represents hydrogen, C₃₋₇ cycloalkyl, NH(C₁₋₄alkylOC₁₋₄alkoxy), NH(C₁₋₄alkyl), N(C₁₋₄alkyl)₂, OC(O)NR₉R₈, NR₈C(O)R₉ or C(O)NR₉R₈;

R₉ and R₈ independently represent hydrogen, C₁₋₄ alkyl or C₃₋₇ cycloalkyl;

m represents zero or an integer from 1 to 4;

n represents 1 or 2;

p is zero or an integer from 1 to 3;

q is an integer from 1 to 3;

r is an integer from 1 to 4;

t is 0, 1 or 2;

provided that when m is 0, p is 2, q, r and n represent 1, R₁, R₂, R₃, R₄, R₅ and R₇ are hydrogen and R is chlorine, R₅ is not iodine;

and pharmaceutically acceptable salts and solvates thereof; process for their preparation and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.